Edwards Lifesciences beat analysts’ estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac procedures, sending its shares up nearly 7% in extended trading.
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
